Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

doi:10.1158/1078-0432.CCR-09-0494

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2009

Voso Maria Teresa, Santini Valeria, Finelli Carlo, Musto Pellegrino, Pogliani Enrico, Angelucci Emanuele, Fioritoni Giuseppe, Alimena Giuliana, Maurillo Luca, Cortelezzi Agostino, Buccisano Francesco, Gobbi Marco, Borin Lorenza, Di Tucci Anna, Zini Gina, Petti Maria Concetta, Martinelli Giovanni, Fabiani Emiliano, Fazi Paola, Vignetti Marco, Piciocchi Alfonso, Liso Vincenzo, Amadori Sergio, Leone Giuseppe

Abstract excerpt

PURPOSE: Epigenetic changes play a role and cooperate with genetic alterations in the pathogenesis of myelodysplastic syndromes (MDS). We conducted a phase II multicenter study on the combination of the DNA-methyltransferase inhibitor 5-azacytidine (5-AZA) and the histone deacetylase inhibitor va...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Cytochrome P-450 CYP2C19

Share to Drug Therapy, Combination

Share to Histone Deacetylase Inhibitors

Share to Methyltransferases

Share to Myelodysplastic Syndromes

Share to Valproic Acid

Source

Open in PubMed

Identifiers

PMID: 19638460
DOI: 10.1158/1078-0432.CCR-09-0494

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19638460-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.PMID 19638460Read ↗

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read ↗

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Semantic proximity Read ↗

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndromeSemantic proximity Read ↗

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.Semantic proximity Read ↗

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.Semantic proximity Read ↗

[Hypomethylating agents for the treatment of myelodysplastic syndromes].Semantic proximity Read ↗

New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic SyndromeSemantic proximity Read ↗

Demethylating agents in myeloid malignanciesSemantic proximity Read ↗

Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromesSemantic proximity Read ↗

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromesSemantic proximity Read ↗

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?Semantic proximity Read ↗

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.